Onco360, the nation's largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Karyopharm's product XPOVIO (selinexor), a first-in-class, XPO-1 inhibitor. XPOVIO is approved in multiple oncology indications, including: (i) in combination with Velcade (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) in patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
"Onco360 is excited to expand our partnership with the team at Karyopharm and become the preferred national specialty pharmacy partner for XPOVIO," said Benito Fernandez, Chief Commercial Officer.
Multiple myeloma is an incurable hematological malignancy involving plasma cells. Only 50 percent of patients diagnosed with multiple myeloma survive past five years following initial diagnosis. The National Cancer Institute estimates that in 2018, approximately 30,770 new patients were diagnosed with multiple myeloma in the U.S.1 Unfortunately, most multiple myeloma patients will relapse following the first complete remission and often require continuous treatment to prevent disease progression. Previously, there were no U.S. Food and Drug Administration (FDA)-approved products or regimens for patients with relapsed or refractory multiple myeloma who failed treatment with lenalidomide, pomalidomide, bortezomib, carfilzomib, and/or daratumumab.
XPOVIO is manufactured by Karyopharm Therapeutics, and has received multiple approvals from the U.S. FDA since 2019.2 XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO-1.
Please see the full Prescribing Information for XPOVIO